RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WGN9,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
Showing items 1–100
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
KTLA,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
ABC27,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Everything Lubbock,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
KRQE,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
abc8news,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Crwe World,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
ProfitQuotes.com,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance1 of $43.2 million as of June 30, 2022; Restated Q1/22: Net revenues of $13.1 million; Q3/22: Net revenues estimated2 to be between $16.5 million to $18.5
MarketScreener,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance1 of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Ticker Tech,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Stockwatch,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WBRC,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WSFA ,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WMTV nbc15,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WALB,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Wave 3 News,
: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
South Carolina News Now,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WCAX,
: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
KCRG.com,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WISTV,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Fox 19,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WLOX,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
News story from WHSV3 on Monday 07 November 2022
WHSV3,
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
14 News,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
KEYC News 12,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WAFB 9,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
KLTV,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Fox 8 WVUE,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
KBTX-TV,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
KAIT-TV,
[1][2] [3] TEL AVIV, Israel and RALEIGH, N.C., Nov. 7, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WECT News 6,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WTVM,
[1][2] [3] TEL AVIV, Israel and RALEIGH, N.C., Nov. 7, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
WDAM - TV,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Morning Star,
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Nov.
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
NBC12,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Benzinga,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Hawaii News Now,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
KCBD,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
News Channel 10,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
PR Newswire,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Biospace,
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of…
RedHill's oral broad-acting antiviral, opaganib to treat Covid-19 receives US patent
Pharmabiz.com,
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the granting by the United States Patent and Trademark…
RedHill’s oral broad-acting antiviral, Opaganib, granted new COVID-19 treatment patent
EurekAlert!,
TEL AVIV, Israel and RALEIGH, NC, October 19, 2022, RedHill Biopharma Ltd. (Nasdaq: RDHL) (RedHill or the Company), a specialty…
RedHill’s oral broad-acting antiviral, Opaganib, granted new COVID-19 treatment patent
Bioengineer.org,
TEL AVIV, Israel and RALEIGH, NC, October 19, 2022, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a…
RedHill’s oral broad-acting antiviral, Opaganib, granted new COVID-19
ScienMag,
TEL AVIV, Israel and RALEIGH, NC, October 19, 2022, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WGN9,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KRQE,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KOIN 6,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
News Channel 11 wjhl.com,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
ABC27,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Ticker Tech,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
News story from News Channel 8 on Wednesday 19 October 2022
News Channel 8 ,
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Kxan,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Your Basin,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
FOX31 Denver KDVR-TV,
Please enter a search term. Please enter a search term. News provided by Oct 19, 2022, 7:00 AM ET USPTO grants new method of…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KTLA,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Spoke,
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
MarketScreener,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Hawaii News Now,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WCAX,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WALB,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
News Channel 10,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WAFB 9,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Fox 19,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KAIT-TV,
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KLTV,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
News story from WHSV3 on Wednesday 19 October 2022
WHSV3,
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WISTV,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KCRG.com,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WDAM - TV,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WMTV nbc15,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
NBC12,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WLOX,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KEYC News 12,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KCBD,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Wave 3 News,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
South Carolina News Now,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
14 News,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WECT News 6,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WBRC,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
KBTX-TV,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Fox 8 WVUE,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WSFA ,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Yahoo! Finance USA,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
WTVM,
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Benzinga,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
PR Newswire,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Biospace,
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and…
Redhill’s oral broad-acting antivirals, Opaganib and RHB-107, inhibit dominant Omicron sub-variant BA.5
EurekAlert!,
-- Results add to previous variant-agnostic efficacy data for both investigational drugs against COVID-19 disease and several…
News story from News Channel 8 on Monday 03 October 2022
News Channel 8 ,
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Everything Lubbock,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Kxan,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
KOIN 6,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
News Channel 11 wjhl.com,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
KRQE,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Your Basin,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
ABC27,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Spoke,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
MarketScreener,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Yahoo! Finance USA,
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in…
Showing items 1–100